Next-generation Sequencing (NGS) Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Next-generation Sequencing (NGS) Market Trends and Insights

Accelerating Adoption of Precision Medicine and Companion Diagnostics

Companion diagnostics linked to targeted therapies are embedding next-generation sequencing into oncology workflows, converting the technology from a research tool to a reimbursable clinical service. The U.S. FDA granted breakthrough designation to 14 NGS-based companion tests during 2024-2025, covering solid tumors such as lung, breast, and melanoma^{[1]U.S. Food and Drug Administration, “Breakthrough Devices Program Updates 2025,” fda.gov}. Medicare’s 2025 coverage expansion for comprehensive genomic profiling eliminated prior-authorization hurdles, boosting test volumes in hospital laboratories. Liquid-biopsy assays that detect circulating tumor DNA are being integrated into earlier treatment lines, with Guardant Health and Foundation Medicine reporting double-digit growth in requisitions in 2025. Although European approvals proceed more slowly, the European Commission’s 2024 proposal to streamline in-vitro diagnostic regulation signals faster clearance pathways after 2027. Collectively, these regulatory trends establish NGS as a clinical mainstay rather than an experimental option.

Continuous Decline in Cost Per Genome and Throughput Gains

Whole-genome sequencing costs fell below USD 500 in 2025 on high-throughput instruments, making population screening economically feasible for public health systems. Ultima Genomics validated a USD 100 genome in peer-reviewed studies during 2024, forcing incumbents to unbundle reagent pricing and rethink revenue models. Illumina’s NovaSeq X delivers 16 terabases per run, enabling laboratories to process thousands of samples weekly. Element Biosciences’ semiconductor-based AVITI platform reduces reagent consumption by 30%, translating cost savings directly to users. These efficiencies are accelerating adoption in middle-income countries that previously considered whole-genome sequencing too expensive for routine diagnostics.

Expansion of Population-Scale Genomics Programs

China, Japan, India, and the United Kingdom each target cohorts exceeding 1 million genomes. China’s Shenzhen National Gene Bank sequenced 800,000 genomes by mid-2025, emphasizing Han ancestry variant databases. Japan’s All Japan Genomic Medicine Program mandates domestic data residency, favoring on-premise sequencing over cloud-only solutions. India’s Genome India Project completed 10,000 genomes across 99 ethnic groups in 2024 and plans to reach 100,000 by 2028. These initiatives consolidate purchasing through national tenders, rewarding suppliers that offer technology transfer and local manufacturing partnerships.

On-Cartridge Sequencing Workflows for Point-of-Care Testing

Integrated cartridges that combine library preparation, amplification, and detection reduce turnaround times from days to hours. Oxford Nanopore’s VolTRAX automates sample-to-sequence workflows for infectious-disease panels. Roche demonstrated a prototype sepsis panel in 2025 that targets emergency departments where empiric antibiotic therapy often precedes culture confirmation. Regulatory uncertainty under CLIA creates approval ambiguity, yet the prospect of same-visit genomic results addresses transport delays that degrade RNA quality in centralized testing.

Fragmented Global Regulatory Landscape for Clinical NGS

Divergent approval pathways across the FDA, EU IVDR, and APAC agencies necessitate region-specific validations, which increase time-to-market and costs. The FDA’s 2024 draft on laboratory-developed tests adds oversight that academic medical centers argue may curb innovation^{[2]U.S. Food and Drug Administration, “Proposed Rule on Laboratory Developed Tests,” fda.gov}. Europe’s IVDR extensions to 2027 leave hundreds of assays in limbo, while China’s regulators demand domestic clinical trials, lengthening launches by up to 24 months. Japan’s conditional approval pathway introduced in 2025 still lacks precise post-market requirements, discouraging smaller firms. Maintaining multiple assay versions dilutes economies of scale and favors companies with deep regulatory resources.

High Capital Outlay for Long-Read & Spatial Platforms

Long-read sequencers, such as PacBio’s Sequel IIe, carry price tags ranging from USD 150,000 to USD 350,000, levels that exceed the capital budgets of most hospital laboratories. Spatial transcriptomics platforms, such as 10x Genomics’ Xenium and NanoString’s CosMx, add an additional USD 250,000–500,000 in hardware costs and require specialized histology staff. Consumables priced at USD 800–1,200 per sample restrict routine use to pharmaceutical R&D and a handful of reference centers. Leasing or reagent-rental schemes shift upfront costs to operating expenses but do not resolve staffing shortages or workflow complexity, so adoption remains confined to well-funded institutes.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Type of Sequencing: Clinical Exomes Outpace Targeted Panels

Whole-exome sequencing is projected to grow at a 14.23% CAGR to 2031 as insurers adopt it for rare-disease diagnostics, redirecting budgets from single-gene tests to comprehensive panels. Targeted resequencing held 38.09% of the next-generation sequencing market share in 2025, driven by oncology panels, yet falling exome costs below USD 200 per sample erode its price advantage. Whole-genome sequencing remains the benchmark for structural variants, although the 30-fold increase in data volume strains hospital IT resources. RNA sequencing is gaining traction in immuno-oncology, and spatial transcriptomics reached USD 180 million in sales in 2025.

The next-generation sequencing market is witnessing rare-disease pathways transition from research to reimbursed care, validating exome tests as first-tier diagnostics. The FDA's approval of the first exome-based neurodevelopmental test in 2025 solidified this transition. Vendors offering turnkey analysis pipelines are gaining favor over those selling raw capacity alone, as community hospitals seek simplicity in bioinformatics.

By Product Type: Instruments Gain as Automation Reduces Dependency

Reagents and consumables captured 69.88% of the next-generation sequencing market size in 2025, but instruments will outpace at 14.39% CAGR through 2031. Benchtop systems that integrate sample prep cut hands-on time and lower point-of-care adoption barriers. Element Biosciences and Singular Genomics employ open-reagent designs that undercut proprietary razor-and-blade models. Illumina’s 2025 reagent-neutral mode acknowledges growing demand for interoperability.

Services, although the smallest segment, are expanding as pharmaceutical sponsors outsource large-scale sequencing to high-throughput centers. Automation platforms from Tecan and Hamilton reduce reagent waste, compressing consumable revenue growth. The shift toward open chemistry compresses margins while broadening the user base, especially among resource-constrained academic institutions.

By Application: Genetic Screening Surges on Newborn Mandates

Drug discovery and personalized medicine accounted for 35.23% of 2025 revenue, but genetic screening is expected to grow at the fastest rate of 14.33% CAGR as governments expand newborn screening panels. The U.K. National Health Service plans to pilot whole-genome sequencing for all newborns in 2025, potentially scaling up to 700,000 infants annually. Japan approved NGS-based spinal muscular atrophy screening in 2024, prompting prefectures to budget for sequencing infrastructure.

Agriculture and animal genomics, although smaller, saw USD 120 million in sequencing spend in 2025 as breeders adopt genomic selection. Multi-omics workflows that merge DNA, RNA, and epigenetic data are becoming feasible on unified platforms, expanding target users beyond traditional molecular labs.

By End User: Academics Sustain Dominance Through Sovereign Funding

Academic institutions accounted for 48.44% of spending in 2025 and are expected to continue growing at 13.98% as national genomics programs route funds through universities. The U.S. NIH allocated USD 290 million in 2025 to the All of Us Program, with sequencing contracts awarded to academic medical centers. China directed USD 180 million toward university-based genomics hubs during 2024-2025.

Hospitals remain the second-largest segment, driven by tumor profiling and inherited-disease testing, yet constrained by limited bioinformatics staff. Pharmaceutical and biotechnology firms spend more per customer but represent a smaller number of accounts. Sequencing-as-a-service offerings target hospitals that lack in-house capacity, while academic users demand open-source tools and data interoperability.

Geography Analysis

North America contributed 41.90% of 2025 revenue, supported by Medicare coverage for comprehensive genomic profiling and the FDA’s expedited approval pathway for companion diagnostics. Canada invested CAD 45 million (approximately USD 33 million) in pediatric rare-disease sequencing in 2025, while Mexico expanded its pharmacogenomic capacity. However, reimbursement remains a challenge to addressing research-oriented workforce shortages in genetic counseling and bioinformatics, tempering growth.

Asia-Pacific is forecast to expand at a 14.21% CAGR, the highest globally. China’s 14th Five-Year Plan earmarked USD 1.2 billion for genomic infrastructure through 2027, and the Shenzhen National Gene Bank surpassed 800,000 genomes by mid-2025. Japan mandates domestic data residency, channeling instrument sales to local facilities, while India plans to reach 100,000 sequenced genomes by 2028. Australia and South Korea advanced reimbursement policies for hereditary disease sequencing in 2024-2025, further fueling regional demand.

Europe’s growth is moderated by IVDR transition delays, which have placed hundreds of lab-developed tests in regulatory limbo through 2025. Germany expanded statutory insurance coverage for tumor profiling in 2024, adding 80,000 tests annually, yet reimbursement rates remain below cost recovery. The U.K. Genomic Medicine Service completed 100,000 whole genomes in 2025 and plans to double by 2027^{[3]NHS England, “Genomic Medicine Service Progress Report 2025,” england.nhs.uk}. France’s national plan committed EUR 670 million (USD 730 million) to 12 regional platforms, though procurement delays pushed installations into late 2025.

The Middle East and Latin America trail in absolute volumes but register rapid project-based uptake. Saudi Arabia’s Genome Program and the UAE’s data-sovereignty rules incentivize local capacity. Brazil piloted NGS-based TB drug-resistance testing in 2024, demonstrating potential public health applications if funding remains stable.

Regulatory Landscape

Clinical NGS continues to be shaped by region-specific approval pathways, which add duplicative validation steps and slow global assay expansion. In the United States, the FDA issued a classification order effective September 11, 2024 that places whole-exome sequencing constituent devices under Class II (510(k)) special controls. The agency is also phasing out broad enforcement discretion for laboratory-developed tests in stages, with Stage 1 beginning May 6, 2025. These steps redirect development priorities toward documented analytical validity, software version control, and bioinformatics verification for regulated clinical use.

In Europe, the IVDR framework continues to tighten performance evaluation and conformity assessment requirements, and Commission Regulation (EU) 2024/1860 (July 9, 2024) extended transition periods for certain legacy IVDs to mitigate supply disruption during the IVDR changeover. China has increased specificity for NGS-related IVD reagents, including classification and technical review expectations, with NMPA guidance issued June 16, 2025 and additional trial technical review points for tumor gene variation detection reagents released June 15, 2026. Overall, the compliance burden is rising for suppliers operating across the FDA, EU IVDR, and NMPA regimes, with closer scrutiny of companion diagnostics and associated reagent kits.

Market Opportunities and Future Outlook

Market opportunities are expanding around integrated sample-to-answer workflows that reduce staffing and informatics requirements for routine sequencing outside large reference centers. In May 2026, Illumina and SPT Labtech unveiled the fireflyGO automation platform for faster, simpler targeted oncology research workflows, reflecting demand for turnkey automation that cuts hands-on time and standardizes execution. Illumina also released DRAGEN v4.5 in April 2026 to extend analysis performance across complex regions and multiomic workflows, supporting labs that want to improve diagnostic yield without rebuilding pipelines for every chemistry update.

A second opportunity sits with platforms and assays that move beyond standard short-read coverage into higher-resolution interpretation, including hard-to-map regions and broader multiomic content. Illumina launched TruPath Genome in February 2026 to improve insight into genomic dark regions and phasing, while Roche launched the AXELIOS 1 sequencing platform in June 2026 based on its SBX technology roadmap, spanning whole-genome and single-cell RNA use cases. On the demand side, cancer screening and earlier interception workflows are pulling sequencing volume toward blood-based approaches, and Caris Life Sciences launched Caris Detect in July 2026, a multi-cancer early detection blood test using ultra-deep whole-genome and transcriptome sequencing combined with AI. That product direction lifts the value of high-throughput reagents and interpretation layers within the market scope.